Targeted sequencing of 341 or more cancer-associated genes (MSK-IMPACT), revealed higher rates of TP53 and CDKN2A alterations in SqD vs UC but no somatic alteration exclusive to the UC or SqD tumors (Supplementary Fig. 1). The gene discussed is TP53; the disease is cancer.